Stereotaxis Robotic Technology to be Featured during 7th Annual Meeting of the Society for Cardiac Robotic Navigation
October 04 2023 - 8:49AM
Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical
robotics for minimally invasive endovascular intervention, today
announced that it will participate in the Society for Cardiac
Robotic Navigation’s 7th Annual Meeting, which will take place
October 19-20 in Washington, DC.
The global physician-led Society for Cardiac
Robotic Navigation (SCRN) is dedicated to establishing a community
and platform for users of robotic technologies in cardiology. The
annual SCRN conference provides a venue for physicians and
healthcare professionals to share best practices, discuss new
clinical literature, and evaluate the latest innovations in
technology.
The program includes a broad range of
presentations, panels, and demonstrations on the use of
Stereotaxis’ robotic technologies with topics ranging from
procedure best practices, the use and value of robotics across a
range of clinical applications, new technology developments, and
the broader context of robotics in endovascular interventions.
Highlighted topics include:
- Developments with artificial
intelligence, machine learning, virtual reality, and robotic
automation
- Robotics for complex ventricular
arrhythmias and congenital heart disease patients
- Fellowship training, best
practices, and practice building with robotics
- Long-distance telerobotic
collaboration during a live case
- Alternative access from the arm
rather than the groin in electrophysiology
- Clinical value and initial
experience using robotics for the treatment of stroke
- Broader context on robotics in
surgery from Intuitive Surgical, FDA, Wall Street, and Big
Tech
The SCRN conference includes a faculty of over
thirty physicians, including many of the pioneering key opinion
leaders in the field, from across North America, Europe, and
Asia.
“It is exciting to see the growing momentum of
robotics reflected in the expansion of the strong, physician-led
Society for Cardiac Robotic Navigation,” said David Fischel,
Stereotaxis Chairman and CEO. “We look forward to learning from and
connecting with the physicians and industry partners at the
conference.”
About StereotaxisStereotaxis (NYSE: STXS) is a
pioneer and global leader in innovative surgical robotics for
minimally invasive endovascular intervention. Its mission is the
discovery, development and delivery of robotic systems,
instruments, and information solutions for the interventional
laboratory. These innovations help physicians provide unsurpassed
patient care with robotic precision and safety, expand access to
minimally invasive therapy, and enhance the productivity,
connectivity, and intelligence in the operating room. Stereotaxis
technology has been used to treat over 100,000 patients across the
United States, Europe, Asia, and elsewhere. For more information,
please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100Investors@Stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2023 to Apr 2024